Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, Rizzieri DA, Delwel R, Buske C, Bohlander SK, Potti A, Löwenberg B.

J Clin Oncol. 2009 Nov 20;27(33):5580-6. doi: 10.1200/JCO.2009.22.2547.

PMID:
19858393
2.

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.

Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW.

J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034.

PMID:
19758616
3.

Systems pathology: a paradigm shift in the practice of diagnostic and predictive pathology.

Donovan MJ, Costa J, Cordon-Cardo C.

Cancer. 2009 Jul 1;115(13 Suppl):3078-84. doi: 10.1002/cncr.24353. Review.

4.

Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study.

Lin DW, Porter M, Montgomery B.

Cancer. 2009 Jul 1;115(13):2863-71. doi: 10.1002/cncr.24324.

5.

Personalized prediction of tumor response and cancer progression on prostate needle biopsy.

Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C.

J Urol. 2009 Jul;182(1):125-32. doi: 10.1016/j.juro.2009.02.135.

PMID:
19450827
6.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010.

7.

Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.

Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H.

Cancer Res. 2007 Jun 1;67(11):5117-25.

8.

Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002.

Rose AJ, Backus BM, Gershman ST, Santos P, Ash AS, Battaglia TA.

Med Care. 2007 May;45(5):440-7.

PMID:
17446830
9.

Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma.

Denberg TD, Glodé LM, Steiner JF, Crawford ED, Hoffman RM.

BJU Int. 2006 Aug;98(2):335-40.

10.

Effect of host age on tumor growth rate in rodents.

Anisimov VN.

Front Biosci. 2006 Jan 1;11:412-22. Review.

PMID:
16146742
11.

Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.

Cancer Res. 2004 Dec 15;64(24):9209-16.

12.

Primary signet ring cell carcinoma of the prostate: report and review of 42 cases.

Fujita K, Sugao H, Gotoh T, Yokomizo S, Itoh Y.

Int J Urol. 2004 Mar;11(3):178-81. Review.

13.

Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR.

Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6.

14.

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.

Moul JW, Wu H, Sun L, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D, Rich NM.

Surgery. 2002 Aug;132(2):213-9.

PMID:
12219014
15.

Effect of young age on prostate cancer survival: a population-based assessment (United States).

Merrill RM, Bird JS.

Cancer Causes Control. 2002 Jun;13(5):435-43.

PMID:
12146848
16.

Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.

Smith CV, Bauer JJ, Connelly RR, Seay T, Kane C, Foley J, Thrasher JB, Kusuda L, Moul JW.

J Urol. 2000 Dec;164(6):1964-7.

PMID:
11061892
17.

Macrophage-recognized molecules of apoptotic cells are expressed at higher levels in AKR lymphoma of aged as compared to young mice.

Itzhaki O, Skutelsky E, Kaptzan T, Siegal A, Michowitz M, Sinai J, Huszar M, Nafar S, Leibovici J.

Adv Exp Med Biol. 2000;479:251-62.

PMID:
10897426
18.

Prostatic signet-ring cell carcinoma: case report and literature review.

Kuroda N, Yamasaki I, Nakayama H, Tamura K, Yamamoto Y, Miyazaki E, Naruse K, Kiyoku H, Hiroi M, Enzan H.

Pathol Int. 1999 May;49(5):457-61. Review.

PMID:
10417691
19.

Mucin-producing carcinoma of the prostate: review of 88 cases.

Saito S, Iwaki H.

Urology. 1999 Jul;54(1):141-4.

PMID:
10414741
20.

Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor.

Bratt O, Kristoffersson U, Olsson H, Lundgren R.

Eur Urol. 1998;34(1):19-24.

PMID:
9676409
Items per page

Supplemental Content

Support Center